Tawee Tanvetyanon

Also affiliated with Moffitt Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer”.

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2742

N/A

1.8DataRank · unranked

70 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa +13 more

Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)

Therapeutic Advances in Medical Oncology(2024)10.1177/17588359241293401

N/A

0.104DataRank · unranked

1 citations

Megan Othus, Sandip Pravin Patel, David E. Gerber, Tawee Tanvetyanon, Hye Sung Kim +10 more

A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps9638

N/A

0DataRank · unranked

1 citations

Richard D. Hall, Andreas Saltos, Gregory A. Otterson, Ming Tan, Sacha Gnjatic +5 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020.v1

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more

S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100738

N/A

0DataRank · unranked

4 citations

Ming-Hui Hsieh, Marianna Koczywas, Janet Tu, Jonathan W. Riess, Tawee Tanvetyanon +8 more